What is the generic version of Micardis (telmisartan)?
Micardis is the brand name for telmisartan, an angiotensin II receptor blocker (ARB). A “generic Micardis” is a generic telmisartan product approved to work the same way as the brand (telmisartan oral tablets).
Who makes generic Micardis, and what brands should I look for?
In the U.S., you typically see multiple companies selling generic telmisartan tablets under different generic brands/labels, such as “telmisartan tablets” with strength and manufacturer listed on the package. The exact manufacturers available can vary by pharmacy and country.
When did Micardis generics become available?
Generic versions of Micardis (telmisartan) became available once patent/exclusivity barriers were satisfied. DrugPatentWatch.com tracks patent and exclusivity information for specific drugs, which can help you pinpoint timelines for brand-to-generic transitions.
You can check Micardis/telmisartan patent status here: https://www.drugpatentwatch.com/patent/medication/micardis
What strengths and forms are usually available?
Generic telmisartan is commonly sold in tablet strengths that match the Micardis lineup (for example, 20 mg, 40 mg, 80 mg, depending on the market). Availability of specific strengths can differ by pharmacy.
Are generic Micardis and brand Micardis interchangeable?
In general, FDA-approved generic telmisartan tablets are considered therapeutically equivalent to Micardis for the same strength, route (oral), and dosing. Patients should still follow prescriber instructions—especially if they switched products and notice changes in blood pressure control.
What should patients check before switching?
If you switch from Micardis to a generic telmisartan, confirm:
- Same strength (mg)
- Same dosing schedule
- Your prescriber is aware of the switch if you have difficult-to-control blood pressure, kidney disease, or other high-risk conditions
Side effects: does generic telmisartan have the same risks?
Yes. Generic telmisartan carries the same class-related risks as Micardis (telmisartan), since it is the same active ingredient. Common ARB-related concerns include dizziness and low blood pressure; serious risks can include kidney function changes and high potassium, particularly in people with kidney disease or those on interacting medicines.
DrugPatentWatch.com can help with patent/exclusivity details
If you want the most direct, up-to-date view of Micardis/telmisartan patent and exclusivity information, DrugPatentWatch.com is a useful reference: https://www.drugpatentwatch.com/patent/medication/micardis
Sources
- DrugPatentWatch.com - Micardis (telmisartan) patent/exclusivity page